Dejan Radeski

60 Shenton Avenue
Joondalup, WA, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications

Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas.

Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas.

Journal: Blood
Published: April 30, 2026

Cytogenetic Testing in Newly Diagnosed Multiple Myeloma: Real World Evidence on Clinical Features and Adverse Outcomes for High Risk Groups.

Cytogenetic Testing in Newly Diagnosed Multiple Myeloma: Real World Evidence on Clinical Features and Adverse Outcomes for High Risk Groups.

Journal: Clinical lymphoma, myeloma & leukemia
Published: October 11, 2025

Australian clinical practice guideline: diagnosis and treatment of idiopathic multicentric Castleman disease.

Australian clinical practice guideline: diagnosis and treatment of idiopathic multicentric Castleman disease.

Journal: Internal medicine journal
Published: July 04, 2025

Indolent relapse after initial aggressive B-cell lymphoma: a single institution experience in the rituximab era.

Indolent relapse after initial aggressive B-cell lymphoma: a single institution experience in the rituximab era.

Journal: Leukemia & lymphoma
Published: October 18, 2024

Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma initially demonstrating near-complete metabolic response to BV-CHEP.

Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma initially demonstrating near-complete metabolic response to BV-CHEP.

Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
Published: July 24, 2024

A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas.

A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 03, 2024

A unique case of splenic rupture secondary to vaccine-induced immune thrombocytopenia managed with splenic embolization.

A unique case of splenic rupture secondary to vaccine-induced immune thrombocytopenia managed with splenic embolization.

Journal: ANZ journal of surgery
Published: November 02, 2021

Diagnosis, management and follow up of peripheral T-cell lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance.

Diagnosis, management and follow up of peripheral T-cell lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance.

Journal: Internal medicine journal
Published: May 09, 2021

Complete remission of stage IV erythrodermic mycosis fungoides with large cell transformation through combination of pralatrexate and romidepsin followed by allogeneic hematopoietic stem cell transplantation.

Complete remission of stage IV erythrodermic mycosis fungoides with large cell transformation through combination of pralatrexate and romidepsin followed by allogeneic hematopoietic stem cell transplantation.

Journal: The Australasian journal of dermatology
Published: February 14, 2021

Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study.

Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study.

Journal: Leukemia & lymphoma
Published: October 07, 2020

Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas.

Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas.

Journal: Haematologica
Published: July 17, 2020

Mycosis fungoides and Sézary syndrome: Australian clinical practice statement.

Mycosis fungoides and Sézary syndrome: Australian clinical practice statement.

Journal: The Australasian journal of dermatology
Published: June 16, 2020
Showing 1-12 of 23

Last Updated: 09/26/2026